Single-Dose Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting Associated With Cisplatin Therapy: Randomized, Double-Blind Study Protocol—EASE - Concepedia

Concepedia

Publication | Open Access

Single-Dose Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting Associated With Cisplatin Therapy: Randomized, Double-Blind Study Protocol—EASE

DOI Full Paper Access

219

Citations

25

References

2011

Year

Steven M. Grunberg, Daniel T. T. Chua, Anish Maru, José Dinis, Suzanne DeVandry, Judith A. Boice, James S. Hardwick, Elizabeth Beckford, Arlene Taylor, Alexandra D. Carides,

Journal of Clinical Oncology

Abstract

Given with ondansetron and dexamethasone, single-dose intravenous fosaprepitant (150 mg) was noninferior to standard 3-day oral aprepitant in preventing CINV during OP and DP.

References

	Year	Citations

Page 1